HF
HUMA icon

HRT Financial’s Humacyte HUMA Stock Holding History

HRT Financial’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-131,524
Closed -$224K – 3029
2025
Q1 		$224K Buy
+131,524
New +$494K ﹤0.01% 1941
2024
Q4 		– Sell
-49,416
Closed -$268K – 2760
2024
Q3 		$268K Buy
+49,416
New +$326K ﹤0.01% 1845
2022
Q3 		– Sell
-58,632
Closed -$188K – 3105
2022
Q2 		$188K Buy
+58,632
New +$326K ﹤0.01% 2266
2021
Q4 		– Sell
-22,229
Closed -$258K – 3572
2021
Q3 		$258K Buy
+22,229
New +$254K ﹤0.01% 2516

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial's HUMA Position: Q2 2025 in Review

HRT Financial sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 131,524 shares — an estimated $224K sold.

HRT Financial first reported a position in HUMA in Q3 2021 and held it in 4 quarters. The position peaked at $268K in Q3 2024. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

  • HRT Financial reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 131,524 Humacyte shares in Q2 2025, an estimated $224K.
  • HRT Financial first reported a position in Humacyte in Q3 2021 and held it in 4 quarters.
  • HRT Financial's Humacyte position peaked at $268K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.